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Last spring, the US National Institutes of
Health (NIH) announced a new policy
calling for the use of both male and female
materials—animals, tissues, cells, and cell
lines—in preclinical research (1). Canada
and the European Union have recently in-
stituted similar policies. Advocates argue
that requiring analysis of sex in preclinical
research will advance scientific understand-
ing of sex differences in human health out-
comes, such as higher rates of adverse drug
events (ADE) in women compared with
men (2). We disagree.
To be useful in addressing health dis-
parities, sex-linked variables in preclinical
materials must effectively model differences
between human men and women. In the
absence of evidence that this is so, the
addition of sex as a variable in all preclinical
studies is likely to introduce conceptual and
empirical errors into research. Biomedical
research institutions and funders can better
remedy sex differences in health outcomes by
focusing on the scientific study of the in-
teraction of sex and gender variables in health
outcomes in human populations.
Sex differences in rates of ADE may be a
result of biological factors, gender-related
social factors, or a combination of sex- and
gender-related variables. “Sex” refers to chro-
mosomal complement, reproductive organs,
or specific hormones related to sexual
reproduction. “Gender” refers to sociocul-
tural norms, expectations, and practices as-
cribed to males and females (3). Gendered
factors, such as women’s propensity to take
multiple pharmaceuticals simultaneously
(polypharmacy) compared with men, and
their greater likelihood to see medical doc-
tors than men, play a well-documented role
in sex differences in health outcomes (4–6).
Take the case of zolpidem (Ambien). In
2013, the Food and Drug Administration
issued an unprecedented advisory reducing
the recommended zolpidem dosage for
women, following reports of higher numbers
of ADE in women compared to men (7).
Since then, researchers have sought the bio-
logical basis for this sex difference in reports
of zolpidem-related ADE. Surprisingly, ex-
perimental studies of sex differences in the
pharmacokinetics and pharmacodynamics
of zolpidem in human men and women
found that body weight, not sex, is the culprit.
Women clear zolpidem from their system
more slowly than men, but body weight elim-
inates the statistical significance of sex as a
variable in clearance of zolpidem (8). Because
body weight, not sex, is the independent
biological variable, sex-based preclinical re-
search protocols would likely not have pre-
dicted sex differences in rates of ADE with
zolpidem.
The zolpidem case provides an example of
the need for studies aimed at uncovering the
embodied interaction of human sex- and
gender-related variables in sex differences in
ADE. Weight is distributed differentially
across male and female bodies. In present-
day American populations, weight may in-
teract with gender-related variables. For
example, higher rates of zolpidem use and
polypharmacy in women compared to men,
as well as biopsychosocial factors, such as
women’s greater sensitivity to and reporting
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of the experience of being impaired, could
increase reports of ADE among women
taking zolpidem. If lower body weight,
greater tendency to use pharmaceuticals,
and higher likelihood of reporting adverse
events are major factors in the higher rates
of ADE among women, policies mandating
the study of sex-related variables in cells, tis-
sues, and animal models are an impoverished
approach to this issue.
Proponents of policies mandating consid-
eration of sex in preclinical research are
concerned about the impact of underrepre-
sentation of female materials on biomedical
research (9–12). But from a human health
perspective, unequal numbers of male and
female animals, or of tissue samples de-
rived from males and females, are only
of concern if male- and female-derived cel-
lular and nonhuman animal materials offer
informative biological models of human
sex differences.
Each form of preclinical biological
material—cell and tissues, cell lines, and
animals—raises distinctive empirical issues
for justifying policies mandating consider-
ation of sex in preclinical materials. In cells
or tissues, sex refers to the presence of XX or
XY chromosomes, but chromosomal comple-
ment is only one biological component of
sex determination and differentiation. XX
and XY cells are not a widely accepted model
for studying sex differences in human bodies.
Beyond the sex chromosomes, endogenous
hormones and diverse genetic factors interact
with gendered environmental cues, such as
use of hormone replacement therapy or dif-
ferential health exposures resulting from the
gendered stratification of paid labor, to create
sex differences in health outcomes.
Studying sex in cell lines is also far from
straightforward. Cell lines are unique lineages
with significant chromosomal mutations, in-
traspecies contamination, and other irregu-
larities compared to primary cells (13).
Whether cell lines can be said to have a sex
is conceptually unclear (14). Many cell lines
derived from male donor cells have been
shown to have lost Y-chromosomal gene ex-
pression, eliminating chromosomal sex as a
meaningful variable (see table 1 in ref. 15).
Some have even proposed that cell lines are
distinct species. Developing a well-validated
cell line is no easy task. Cell lines are odd-
acting lineages and no two paired cell lines
are likely to have enough similarities to be
valid models of sex differences (14).
Animal models are no less complex. Many
in the scientific community have critically
discussed the practicalities of a mandate that
requires the study of sex-related variables in
laboratory animals. For example, some sug-
gest that studying females as well as males in
adequately powered numbers will be
expensive and space-intensive. Thus, it
is particularly important that this ele-
ment of institutional policies be strongly
evidence-based.
Animal models are regularly used to study
aspects of sex, but sex dimorphism, sexual
behavior, and their developmental pathways
vary considerably among common labo-
ratory species. Just like a cell in vitro, a
laboratory animal at different stages in its
own ontogeny may not effectively model—
both for hormonal-milieu and gender-
contextual reasons—the “environment” of
the adult human male or female. Important
human life-cycle traits, such as extended
life span and menopause, are poorly repre-
sented in animal models yet contribute to
health outcome differences between human
men and women.
Sociality in rodents illustrates the potential
problems withmodeling human sex differences
in nonhuman model organisms. Prendergast
et al. (16) reviewed whether female mice are
more variable than males and hence require
testing at each stage of the estrus cycle. Con-
trary to a common presumption, they found
that males are more variable than females for
several endpoints and that estrus-cycle–
related variability does not need to be con-
trolled in female mice. An equally striking
result of their study, however, was the inci-
dental identification of a profound, non–sex-
related source of variation in mice. Group vs.
individual caging appears to be a major and
unexpected variable mediating outcomes in
mouse studies: group housing increased
variability in both males and females by
37% (16). This finding highlights the
need for rigorous validation of animal
models for the study of any particular hu-
man biological sex-difference pathway.
Giving special salience to the variable of
sex without attending to interacting species-
specific variables, such as animals per cage,
may produce findings of questionable rele-
vance to human health.
We support basic research on sex in
preclinical materials and affirm the need for
better research on sex differences in ADE.
But we are concerned that mandates, such as
that of the NIH, dedicate institutional re-
sources to the study of basic sex differences in
preclinical materials at an opportunity cost to
sex-gender–based lines of research more rel-
evant to understanding women’s and men’s
health disparities. Diverse gender- and sex-
linked variables, including body weight/body
mass index, hormones, rates of polyphar-
macy, and age play a role in human sex dif-
ferences in health outcomes, such as overall
rates of ADE.
Proponents acknowledge that analysis of
sex in basic clinical materials cannot model
these variables, but view policies such as the
new NIH mandate as an imperfect step in
the right direction. But the new policy’s focus
on nonhypothesis-driven documentation of
sex differences in basic laboratory research
is more likely to introduce conceptual and
empirical problems in research on sex and
gender than bring new clarity to differences
in men’s and women’s health outcomes. If
the goal is to advance human health, we see
a stronger empirical basis for directed fund-
ing initiatives in two areas: scientific vali-
dation of preclinical models for studying
human sex differences, and human studies
of the interaction of sex- and gender-related
variables in producing health outcomes that
vary by sex.
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